Staff Turnover or Insufficient Staff

• Frequent changes in site coordinator roles in the last 12–18 months
• No backup personnel identified for key functions
• Lack of documented GCP training for new hires

3. Incomplete or Poorly Maintained Regulatory Documentation

• Missing or outdated CVs and training logs
• No evidence of past EC/IRB approval letters or protocol submissions
• Audit reports reveal history of non-compliance

4. Limited or Inadequate Infrastructure

• No access-controlled storage for Investigational Product (IP)
• Lack of calibrated equipment for sample handling or diagnostics
• No designated monitoring area or workspace for CRAs
• Infrastructure checklists not aligned with protocol requirements (e.g., ECG, cold chain)

5. Unrealistic Patient Recruitment Estimates

• Claims to enroll large numbers without historical evidence
• No defined patient database or referral network
• High screen failure or dropout rates in previous studies

6. Poor Understanding of Protocol or Therapeutic Area

• PI unfamiliar with inclusion/exclusion criteria
• Staff unsure about specific assessments, sample handling, or visit windows
• No history of similar therapeutic studies

7. Delayed Ethics Committee Timelines

• EC meets infrequently or has unpredictable turnaround times
• History of delayed start-up in past trials due to EC constraints
• Limited experience handling international sponsor requirements

8. Inadequate Data Entry and IT Systems

• Unstable internet connection or limited access to EDC platforms
• No secure, compliant data backup systems
• History of delayed CRF entries or unresolved queries

9. Poor Engagement During Feasibility Process

• Delayed or incomplete feasibility questionnaire responses
• Uncooperative attitude during site tours or PI interviews
• Failure to provide requested documents like SOPs, CVs, or temperature logs

10. Negative Audit History

• Site has been cited by regulatory agencies for major findings
• Failure to implement corrective and preventive actions (CAPA)
• Repeat protocol deviations across multiple trials

Documenting and Escalating Red Flags

All red flags should be documented in the feasibility tracker and shared with the sponsor feasibility team. If red flags cannot be resolved before trial initiation, the site should either be disqualified or closely monitored. Use forms like:

• Site Evaluation Summary with justification
• Feasibility Risk Escalation Template
• PI Interview Documentation Template

Templates are available through platforms like Pharma SOPs to standardize evaluation and record-keeping.

Mitigation Strategies for Sites with Minor Red Flags

• Provide additional training to staff pre-initiation
• Introduce sub-investigators to support busy PIs
• Request SOP updates or provide sponsor templates
• Use remote monitoring to oversee compliance early
• Delay activation until infrastructure gaps are resolved

Integrating Red Flags into Site Scoring Systems

Develop a feasibility scorecard that penalizes red flag indicators with negative weights. Example scoring:

• PI Availability (−20 for conflicts, +30 for full engagement)
• Staff Turnover (−15 if turnover ≥2 roles in 12 months)
• Infrastructure Gaps (−10 per missing equipment item)
• Recruitment Reliability (+25 for historical actuals, −25 for unverifiable projections)

Conclusion

Spotting red flags during site feasibility is essential for building a reliable and inspection-ready trial network. Sponsors and CROs must use structured tools, scoring models, and team interviews to vet sites thoroughly. While some red flags can be addressed with mitigation plans, persistent or critical issues should lead to disqualification. A cautious, documented approach ensures that your study begins with the right partners and avoids future roadblocks.